Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
FDA issued draft guidance intended to assist trading partners in standardizing the data contained in the product tracing infor- mation that must be provided, captured, and maintained under section 582 of the 2013 Drug Supply Chain Security Act. An additional guidance was issued to interpret the terms used in the definitions of “suspect” and “illegitimate” products set forth is section 58, including verification and notification obligations.
[/membership]